$CVS (-0,19%) has presented its quarterly figures for Q4 2025 and they read well at first glance:
- Revenue (expected): USD 103.63 billion
- Revenue (reported): USD 105.70 billion
- EPS (expected): USD 1.00
- EPS (reported): USD 1.09
Despite these positive results, the market reacted rather cautiously. An indication that investors have concerns for the future beyond the pure figures.
The challenges include:
- Changes in the Pharmacy Benefit Manager (PBM) sector
- Rising prices for branded drugs, which could lead to additional costs of USD 25 billion
- Increased competition in the Medicare Advantage market
For 2026 confirms $CVS (-0,19%) confirms its outlook with an Adjusted EPS range of $7.00-$7.20 and sales of at least $400bn, demonstrating management's continued commitment to long-term growth.
How do you assess the current situation? Is last month's share price decline exaggerated given the solid results? Or are you more concerned about the structural challenges in the healthcare sector?